close
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Metsera, Inc. - Common Stock (NQ:MTSR)

52.97 +0.10 (+0.19%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,179,265
Open 52.79
Bid (Size) 52.12 (1)
Ask (Size) 53.84 (1)
Prev. Close 52.87
Today's Range 52.59 - 52.99
52wk Range 12.30 - 54.47
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Down 44%, Should You Buy the Dip on Viking Therapeutics?
The company is readying to take on pharma giants Novo Nordisk and Eli Lilly. 
Via The Motley Fool
Where Will Pfizer Be in 5 Years?
Pfizer is working hard to deal with some big headwinds it has coming up, but in five years, this should all be in the past. 
Via The Motley Fool
Topics Intellectual Property World Trade

Performance

YTD
+99.9%
+99.9%
1 Month
+54.8%
+54.8%
3 Month
+24.7%
+24.7%
6 Month
+191.4%
+191.4%
1 Year
+99.9%
+99.9%

More News

Read More
SHAREHOLDER RIGHTS ALERT: Halper Sadeh LLC Investigates PINC, MTSR, HOUS, ODP on Behalf of Shareholders
From Halper Sadeh LLC
Via GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Premier, Inc. (Nasdaq – PINC), Metsera, Inc. (Nasdaq – MTSR), Anywhere Real Estate Inc. (NYSE – HOUS), The ODP Corporation (Nasdaq – ODP)
From Brodsky & Smith LLC
Via GlobeNewswire
Down 50%, Should You Buy the Dip on Pfizer?
Via The Motley Fool
Topics Intellectual Property
3 Reasons to Buy Pfizer Stock Now
Via The Motley Fool
Viking Therapeutics Ignites Retail-Trader Frenzy Amid Deal Speculation, Upcoming Trial Catalysts
Via Stocktwits
2 Reliable Dividend Stocks With Yields Above 6% That You Can Buy With $100 in October
Via The Motley Fool
Topics Intellectual Property
3 Things You Need to Know if You Buy Pfizer Today
Via The Motley Fool
Topics Intellectual Property
Got $200? 2 Healthcare Stocks to Buy and Hold Forever
Via The Motley Fool
Metsera Reports Up To 14% Weight Loss In Phase 2b Obesity Trial
Via Benzinga
Pfizer Just Reminded Investors Why You Should Never Count Its Stock Out
Via The Motley Fool
Metsera Reports Positive Phase 2b Results for First- and Best-in-Class Ultra-long Acting GLP-1 RA Candidate MET-097i, Enabling Rapid Transition into Phase 3
From Metsera, Inc.
Via GlobeNewswire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PINC, MTSR, HOUS, ODP on Behalf of Shareholders
From Halper Sadeh LLC
Via GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Premier, Inc. (Nasdaq – PINC), Metsera, Inc. (Nasdaq – MTSR), Anywhere Real Estate Inc. (NYSE – HOUS), The ODP Corporation (Nasdaq – ODP)
From Brodsky & Smith LLC
Via GlobeNewswire
3 High-Yield Dividend Stocks to Buy Now for a Lifetime of Passive Income
Via The Motley Fool
Topics Artificial Intelligence Economy
Down 55%, Should You Buy the Dip on Pfizer?
Via The Motley Fool
Topics Intellectual Property
Is Pfizer Stock a Buy After Its $5 Billion GLP-1 Bet?
Via The Motley Fool
Pfizer is Locking in New Growth Through a New Acquisition
Via MarketBeat
Topics Artificial Intelligence
Did Pfizer Just Give Investors 7 Billion Reasons to Buy Its Stock?
Via The Motley Fool
Topics Intellectual Property
2 Top Passive Income Stocks to Buy Now
Via The Motley Fool
Topics Bonds Economy Lawsuit
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ARIS, MTSR, GTLS, MURA on Behalf of Shareholders
From Halper Sadeh LLC
Via GlobeNewswire
METSERA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Metsera, Inc. - MTSR
From Kahn Swick & Foti, LLC
Via Business Wire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ARIS, MTSR, ODP, SMLR on Behalf of Shareholders
From Halper Sadeh LLC
Via GlobeNewswire
What's Pfizer Getting in Its $7.3 Billion Metsera Buyout?
Via The Motley Fool

Frequently Asked Questions

Is Metsera, Inc. - Common Stock publicly traded?
Yes, Metsera, Inc. - Common Stock is publicly traded.
What exchange does Metsera, Inc. - Common Stock trade on?
Metsera, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Metsera, Inc. - Common Stock?
The ticker symbol for Metsera, Inc. - Common Stock is MTSR on the Nasdaq Stock Market
What is the current price of Metsera, Inc. - Common Stock?
The current price of Metsera, Inc. - Common Stock is 52.97
When was Metsera, Inc. - Common Stock last traded?
The last trade of Metsera, Inc. - Common Stock was at 10/13/25 04:00 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Starting at $3.75/week.

Subscribe Today